Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. (KLDO): 4 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.2 months
D/E 3.73 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Kaleido Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4K
Cash
$40.6M
Quarterly Burn
$17.2M
Runway
7.2 mo
Revenue
$492K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| hantz financial services, inc. | 350 | $0 |
| rmg wealth management llc | 70 | $0 |
Frequently asked questions
How many drug candidates are in Kaleido Biosciences, Inc.'s pipeline?
Kaleido Biosciences, Inc. (KLDO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kaleido Biosciences, Inc.'s lead drug candidate?
Kaleido Biosciences, Inc.'s most advanced tracked candidate is kb109 (Preclinical) for Mild to moderate COVID-19.
What is Kaleido Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kaleido Biosciences, Inc. has approximately 7.2 months of cash runway.
What is Kaleido Biosciences, Inc.'s market capitalization?
Kaleido Biosciences, Inc.'s market capitalization is approximately $4K.
Who is the CEO of Kaleido Biosciences, Inc.?
Daniel L Menichella is the chief executive officer of Kaleido Biosciences, Inc. (KLDO).
Get the full picture on Kaleido Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.